Drug intelligence / Profile preview

IMG KLH

Development stage: Preclinical
Lead developer: Stellar Biotechnologies
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intramuscular, Intradermal, Intravenous, Oral, Intranasal, Inhalation

Overview

IMG KLH is a proprietary, pharmaceutical-grade form of Keyhole Limpet Hemocyanin (KLH), a large, highly immunogenic protein. Stellar Biotechnologies is developing this asset, intending to complete its development and regulatory processes for a commercial launch. KLH is widely recognized for its use as a carrier protein in conjugate vaccines to enhance the immune response against haptens or weak antigens, and it also exhibits non-specific immune-stimulatory properties.

Beyond the preview

Go deeper on IMG KLH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMG KLH.

Explore the full profile